Pomalidomide and Hematologic toxicities
Result of checking the interaction of drug Pomalidomide and disease Hematologic toxicities for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of pomalidomide has been associated with hematological toxicities, followed by anemia and thrombocytopenia. It is recommended to monitor patients for hematologic toxicities, especially neutropenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter and depending on findings, patients may require dose interruption and/or modification. Close monitoring is recommended.